High mineral affinity of polyphosphoester ionomer-phospholipid vesicles

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 2, 2013, Pages 318-325

  Ikeuchi, Ryota ^a   Iwasaki, Yasuhiko ^a  

^a KANSAI UNIVERSITY   (Japan)

Author keywords

Amphiphilic polymer; Bone specific drug carrier; Polyphosphoester ionomer; Surface modification; Vesicle

Indexed keywords

1 ,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE; AMPHIPHILIC POLYMERS; AMPHIPHILICS; BONE AFFINITY; DRUG CARRIER; ENZYMATIC DEGRADATION; HEMOLYTIC ACTIVITY; HIGHLY-IONIZED; MC3T3-E1; MC3T3-E1 CELL; MINERAL AFFINITY; MOLAR FRACTIONS; OSTEOBLASTIC CELLS; PHOSPHOLIPID VESICLES; POLYPHOSPHOESTERS; RELEASE RATE; SODIUM SALT; VESICLE;

BONE; DRUG DELIVERY; IONOMERS; LIPOSOMES; SURFACE TREATMENT;

ENZYME IMMOBILIZATION;

6 CARBOXYFLUORESCEIN; DIOLEOYLPHOSPHATIDYLCHOLINE; PHOSPHOLIPID DERIVATIVE; POLYPHOSPHOESTER IONOMER; SODIUM; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ARTICLE; BILAYER MEMBRANE; BINDING AFFINITY; BONE MINERAL; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMOBILIZATION; LIPID COMPOSITION; MOUSE; NONHUMAN; NORMAL HUMAN; OSTEOBLAST; PHOSPHOLIPID VESICLE; PHYSICAL CHEMISTRY;

ADSORPTION; ANIMALS; CELL DEATH; CELL SURVIVAL; FLUORESCEINS; HEMOLYSIS; HUMANS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MINERALS; ORGANOPHOSPHATES; OSTEOBLASTS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASES A2; POLYESTERS; STATIC ELECTRICITY; UNILAMELLAR LIPOSOMES;

EID: 84872683303     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34321     Document Type: Article

References (45)

1. Dahl SG, Allain P, Marie P., Mauras Y, Boivin G, Ammann P., Tsouderos Y, Delmas PD, Christiansen C. Incorporation and distribution of strontium in bone. Bone 2001; 28: 446-453.
2. Canalis RF, Lechago J. Tetracycline bone labeling: An improved technique using incident fluorescence. Ann Otol Rhinol Laryngol 1982; 91: 160-162.
3. Pautke C, Vogt S, Kreutzer K., Haczek C, Wexel G, Kolk A., Imhoff AB, Zitzelsberger H, Milz S, Tischer T. Characterization of eight different tetracyclines: Advances in fluorescence bone labeling. J Anat 2010; 217: 76-82.
4. Bartl R, Frisch B, von Tresckow E, Bartl C. Bisphosphonates in Medical Practice: Actions, Side Effects, Indications, Strategies. Berlin: Springer-Verlag; 2007. 33 p.
5. Russell RG, Xia Z, Dunford J.E., Oppermann U., Kwaasi A, Hulley PA, Kavanagh K.L., Triffitt JT, Lundy MW, Phipps RJ, Barnett B.L., Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007; 1117: 209-257.
6. Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 2011; 12: 397-408.
7. Vatassery GT, Armstrong WD, Singer L. Determination of hydroxyl content of calcified tissue mineral. Endocrine 1997; 6: 203-206.
8. Rogers MJ, Watts DJ, Russell RGR, Overview of bisphosphonates. Cancer 1997; 80: 1652-1660.
9. Bauss F, Esswein A, Reiff K., Sponer G, Muller-Beckmann B. Effect of 17b-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17b-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int 1996; 59: 168-173.
10. Klenner T, Valenzuela-Paz P, Keppler B.K., Angres G., Scherf HR, Wingen F, Amelung F, Schmahl D. Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 1990; 17: 253-259.
11. Gil L, Han Y, Opas E.E., Rodan GA, Ruel R, Seedor JG, Tyler P.C., Young RN Prostaglandin E2-bisphosphonate conjugates: Potential agents for treatment of osteoporosis. Bioorg Med Chem 1999; 7: 901-919.
12. Uludag H, Kousinioris N, Gao T., Kantoci D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol Prog 2002; 18: 604-611.
13. Gittens SA, Bansal G, Zernicke R.F., Uludag H. Designing proteins for bone targeting. Adv Drug Deliv Rev 2005; 57: 1011-1036.
14. Hengst V, Oussoren C, Kissel T., Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Int J Pharm 2007; 331: 224-227.
15. Anada T, Takeda Y, Honda Y., Sakurai K, Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett 2009; 19: 4148-4150.
16. Wang G, Babadaǧli ME, Uludaǧ H. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds. Mol Pharm 2011; 8: 1025-1034.
17. Wang G, Mostafa ZM, Incani V, Kucharski C., Uludaǧ H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res A 2012; 100: 684-693.
18. Grit M, Crommelin DJA. Chemical stability of liposomes: Implications for their physical stability. J Controlled Release 1991; 17: 217-224.
19. Woodle MC, Lasic DD Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171-199.
20. Hayashi H, Kono K, Takagishi T. Temperature-controlled release property of phospholipid vesicles bearing a thermo-sensitive polymer. Biochim Biophys Acta 1996; 1280: 127-134.
21. Sunamoto J, Sato T, Hirota M., Fukushima K, Hiratani K, Hara K. A newly developed immunoliposome - An egg phosphatidylcholine liposome coated with pullulan bearing both a cholesterol moiety and an IgMs fragment. Biochim Biophys Acta 1987; 898: 323-330.
22. Katayama K, Iwasaki Y. Synthesis of biocompatible polymers having bisphosphonate-like activity and their influence on osteoblast functions. Biomaterials 2011; 33: 95.
23. Zhao Z, Wang J, Mao H.Q., Leong KW Polyphosphoesters in drug and gene delivery. Macromol Biosci 2009; 9: 1154-1164.
24. Monge S, Canniccioni, B Graillot, A Robin, JJ. Phosphorus-containing polymers: A great opportunity for the biomedical field. Biomacromolecules 2011; 12: 1973-1982.
25. Wachiralarpphaithoon C, Iwasaki Y, Akiyoshi K. Enzyme-degradable phosphorylcholine porous hydrogels cross-linked with polyphosphoesters for cell matrices. Biomaterials 2007; 28: 984-993.
26. Libiszowski J, Kałuzynski K, Penczek S. Polymerization of cyclic esters of phosphoric acid. VI. Poly(alkyl ethylene phosphates). Polymerization of 2-alkoxy-2-oxo-1, 3, 2-dioxaphospholans and structure of polymers. J Polym Sci Polym Chem Ed 1978; 16: 1275-1283.
27. Iwasaki Y, Yamaguchi E. Synthesis of well-defined thermoresponsive polyphosphoester macroinitiators using organocatalysts. Macromolecules 2010; 43: 2664-2666.
28. Iwasaki Y, Kawakita T, Yusa S. Thermoresponsive polyphosphoesters bearing enzyme-cleavable side chains. Chem Lett 2009; 38: 1054-1055.
29. Ohya Y, Takeda S, Shibata Y., Ouchi T, Maruyama A. Preparation of highly stable biodegradable polymer micelles by coating with polyion complex. Macromol Chem Phys 2010; 211: 1750-1756.
30. Franceschi RT, Iyer BS, Cui Y. Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3E1 cells. J Bone Miner Res 1994; 9: 843-854.
31. Wang D, Christensen K, Chawla K., Xiao G, Krebsbach PH, Franceschi RT Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 1999; 14: 893-903.
32. Ananthapadmanabhan KP, Goddard ED, Turro N.J., Kuo PL Fluorescence probes for critical micelle concentration determination. Langmuir 1985; 1: 352-355.
33. Meyer J., Whitcomb L, Collins D. Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochem Biophys Res Commun 1994; 199: 433-438.
34. Colletier JP, Chaize B, Winterhalter M., Fournier D. Protein encapsulation in liposomes: Efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002; 2: 9-16.
35. Brgles M, Jurasin D, Sikiric M.D., Frkanec R., Tomasic J. Entrapment of ovalbumin into liposomes - Factors affecting entrapment efficiency, liposome size, and zeta potential. J Liposome Res 2008; 18: 235-248.
36. Huang YY, Chung TW, Wu CI Effect of saturated/unsaturated phosphatidylcholine ratio on the stability of liposome-encapsulated hemoglobin. Int J Pharm 1998; 172: 161-167.
37. Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci 1982; 30: 2123-2136.
38. Ikeuchi R., Iwasaki Y. Synthesis of amphiphilic polyphosphoester ionomers for surface modification of small unilamellar phospholipid vesicles. Trans Mater Res Soc Jpn 2012; in press.
39. Straubinger RM, Hong K, Friend D.S., Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. Cell 1983; 32: 1069-1079.
40. Wenk MR, Fahr A, Reszka R., Seelig J. Paclitaxel partitioning into lipid bilayers. J Pharm Sci 1996; 85: 228-231.
41. Bernsdorff C, Reszka R, Winter R. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J Biomed Mater Res 1999; 46: 141-149.
42. Tanigo T, Takaoka R, Tabata Y. Sustained release of water-insoluble simvastatin from biodegradable hydrogel augments bone regeneration. J Control Release 2010; 143: 201-206.
43. Jørgensen K, Kiebler T., Hylander I, Vermehren C. Interaction of a lipid-membrane destabilizing enzyme with PEG-liposomes. Int J Pharm 1999; 183: 21-24.
44. Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005; 44: 68-97.
45. Popplewell JF, Swann MJ, Freeman N.J., McDonnell C., Ford RC, Quantifying the effects of melittin on liposomes. Biochim Biophys Acta 2007; 1768: 13-20.